• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

巴雷特食管的分化与增殖以及抑酸作用

Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression.

作者信息

Ouatu-Lascar R, Fitzgerald R C, Triadafilopoulos G

机构信息

Gastroenterology Section, Palo Alto Veterans Affairs Health Care System, Palo Alto, CA, USA.

出版信息

Gastroenterology. 1999 Aug;117(2):327-35. doi: 10.1053/gast.1999.0029900327.

DOI:10.1053/gast.1999.0029900327
PMID:10419913
Abstract

BACKGROUND & AIMS: Maintenance of normal epithelial differentiation and proliferation is an important goal in cancer chemoprevention. Because acid has a dynamic effect on cell proliferation/differentiation of Barrett's esophagus (BE) ex vivo, we investigated the relationship between differentiation, proliferation, and dysplasia in BE biopsy specimens and explored the role of normalization of intraesophageal pH in altering the BE phenotype.

METHODS

Endoscopic biopsy specimens of BE (with or without dysplasia) were analyzed for (1) villin, a differentiation marker, by immunoblotting; (2) proliferating cell nuclear antigen (PCNA), a proliferation marker, by immunohistochemistry; and (3) dysplasia by histology before and after 6 months of normalization of intraesophageal pH (confirmed by 24-hour pH monitoring) with lansoprazole.

RESULTS

At baseline, there was a negative correlation (r = -0.79) between villin and PCNA expression. Six months later, PCNA expression decreased and villin expression increased (P < 0.001) in 24 patients whose intraesophageal pH normalized. Fifteen patients had persistently pathological intraesophageal acid reflux and no change in villin or PCNA expression. There were no differences in the occurrence of dysplasia after 6 months in either group.

CONCLUSIONS

In BE, there is an inverse relationship between villin and PCNA. In turn, dysplasia is unrelated to villin expression and well correlated with PCNA expression. Complete symptom eradication with lansoprazole does not guarantee normalization of intraesophageal pH profile in BE patients. Effective intraesophageal acid suppression favors differentiation and decreases proliferation. The intriguing possibility that acid suppression can be used to prevent dysplasia remains to be explored.

摘要

背景与目的

维持正常上皮分化和增殖是癌症化学预防的一个重要目标。由于酸对巴雷特食管(BE)细胞增殖/分化具有动态影响,我们研究了BE活检标本中分化、增殖和发育异常之间的关系,并探讨了食管内pH值正常化在改变BE表型中的作用。

方法

对BE(有或无发育异常)的内镜活检标本进行以下分析:(1)通过免疫印迹法检测绒毛蛋白(一种分化标志物);(2)通过免疫组织化学检测增殖细胞核抗原(PCNA,一种增殖标志物);(3)在使用兰索拉唑使食管内pH值正常化6个月(通过24小时pH监测确认)前后,通过组织学检查发育异常情况。

结果

基线时,绒毛蛋白和PCNA表达呈负相关(r = -0.79)。6个月后,食管内pH值正常化的24例患者中,PCNA表达下降,绒毛蛋白表达增加(P < 0.001)。15例患者食管内持续存在病理性酸反流,绒毛蛋白或PCNA表达无变化。两组6个月后发育异常的发生率无差异。

结论

在BE中,绒毛蛋白和PCNA呈负相关。反过来,发育异常与绒毛蛋白表达无关,与PCNA表达密切相关。使用兰索拉唑完全消除症状并不能保证BE患者食管内pH值曲线正常化。有效的食管内酸抑制有利于分化并减少增殖。酸抑制可用于预防发育异常这一有趣的可能性仍有待探索。

相似文献

1
Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression.巴雷特食管的分化与增殖以及抑酸作用
Gastroenterology. 1999 Aug;117(2):327-35. doi: 10.1053/gast.1999.0029900327.
2
Importance of adequate acid suppression in the management of Barrett's esophagus.
Gastroenterology. 1999 Dec;117(6):1509-10. doi: 10.1016/s0016-5085(99)70315-x.
3
Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus.巴雷特食管患者反流症状完全消除并不能保证食管内酸反流正常化。
Am J Gastroenterol. 1998 May;93(5):711-6. doi: 10.1111/j.1572-0241.1998.211_a.x.
4
Maximal acid reflux control for Barrett's oesophagus: feasible and effective.巴雷特食管的最大胃酸反流控制:可行且有效。
Aliment Pharmacol Ther. 2001 Apr;15(4):519-24. doi: 10.1046/j.1365-2036.2001.00958.x.
5
Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus.高剂量质子泵抑制剂治疗使食管pH值正常化并不会导致巴雷特食管消退。
Am J Gastroenterol. 1997 Apr;92(4):582-5.
6
Barrett's esophagus: acid suppression, but no regression.巴雷特食管:抑酸治疗,但无逆转。
Am J Gastroenterol. 1997 Apr;92(4):556-8.
7
Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus.罗非昔布抑制环氧化酶2的表达和活性,并减少巴雷特食管中的细胞增殖。
Gastroenterology. 2002 Jul;123(1):60-7. doi: 10.1053/gast.2002.34244.
8
The dose of omeprazole required to achieve adequate intraesophageal acid suppression in patients with gastroesophageal junction specialized intestinal metaplasia and Barrett's esophagus.胃食管结合部特殊型肠化生和 Barrett 食管患者实现食管内充分抑酸所需的奥美拉唑剂量。
Dig Dis Sci. 2013 Aug;58(8):2253-60. doi: 10.1007/s10620-013-2763-1. Epub 2013 Jul 4.
9
Dynamic effects of acid on Barrett's esophagus. An ex vivo proliferation and differentiation model.酸对巴雷特食管的动态影响。一种体外增殖与分化模型。
J Clin Invest. 1996 Nov 1;98(9):2120-8. doi: 10.1172/JCI119018.
10
Lack of predictors of normalization of oesophageal acid exposure in Barrett's oesophagus.巴雷特食管中食管酸暴露正常化的预测因素缺失。
Aliment Pharmacol Ther. 2005 Oct 1;22(7):627-33. doi: 10.1111/j.1365-2036.2005.02626.x.

引用本文的文献

1
Barrett's esophagus: A review.巴雷特食管:综述
World J Gastrointest Pathophysiol. 2025 Sep 22;16(3):107273. doi: 10.4291/wjgp.v16.i3.107273.
2
Revisiting Proton Pump Inhibitors as Chemoprophylaxis Against the Progression of Barrett's Esophagus.重新审视质子泵抑制剂在预防 Barrett 食管进展中的化学预防作用。
Curr Gastroenterol Rep. 2023 Dec;25(12):374-379. doi: 10.1007/s11894-023-00905-5. Epub 2023 Nov 9.
3
Variation in Fatty Acid Synthase, Ki67 and p53 Esophageal Mucosa Expressions in Barrett's Esophagus Patients Treated for One Year with Two Esomeprazole Different Regimens.
使用两种不同埃索美拉唑治疗方案对巴雷特食管患者进行一年治疗后,其食管黏膜中脂肪酸合酶、Ki67和p53表达的变化
Curr Issues Mol Biol. 2023 May 29;45(6):4701-4715. doi: 10.3390/cimb45060299.
4
Nrf2/Keap1-Pathway Activation and Reduced Susceptibility to Chemotherapy Treatment by Acidification in Esophageal Adenocarcinoma Cells.Nrf2/Keap1通路激活与食管腺癌细胞酸化导致化疗敏感性降低
Cancers (Basel). 2021 Jun 4;13(11):2806. doi: 10.3390/cancers13112806.
5
Discontinuing Long-Term PPI Therapy: Why, With Whom, and How?停止长期使用质子泵抑制剂(PPI)治疗:为什么、针对谁以及如何停药?
Am J Gastroenterol. 2018 Apr;113(4):519-528. doi: 10.1038/ajg.2018.29. Epub 2018 Mar 20.
6
Proton Pump Inhibitors Display Antitumor Effects in Barrett's Adenocarcinoma Cells.质子泵抑制剂在巴雷特腺癌细胞中显示出抗肿瘤作用。
Front Pharmacol. 2016 Nov 25;7:452. doi: 10.3389/fphar.2016.00452. eCollection 2016.
7
Silencer-of-Death Domain Mediates Acid-Induced Decrease in Cell Apoptosis in Barrett's Associated Esophageal Adenocarcinoma Cells.死亡结构域沉默蛋白介导巴雷特相关食管腺癌细胞中酸诱导的细胞凋亡减少。
J Pharmacol Exp Ther. 2017 Jan;360(1):14-22. doi: 10.1124/jpet.116.236620. Epub 2016 Oct 18.
8
Barrett's esophagus in 2016: From pathophysiology to treatment.2016年的巴雷特食管:从病理生理学到治疗
World J Gastrointest Pharmacol Ther. 2016 May 6;7(2):190-206. doi: 10.4292/wjgpt.v7.i2.190.
9
Carcinogenesis of Barrett's esophagus: a review of the clinical literature.巴雷特食管的致癌作用:临床文献综述
Clin J Gastroenterol. 2013 Dec;6(6):399-414. doi: 10.1007/s12328-013-0412-z. Epub 2013 Aug 14.
10
Barrett's oesophagus: frequency and prediction of dysplasia and cancer.巴雷特食管:发育异常和癌症的发生率及预测
Best Pract Res Clin Gastroenterol. 2015 Feb;29(1):125-38. doi: 10.1016/j.bpg.2015.01.001. Epub 2015 Jan 20.